GSK to acquire 35Pharma for $950m.

GSK, a major British-based multinational biopharmaceutical company, agreed to acquire 35Pharma, a clinical-stage biopharmaceutical company, for $950m. "In recent years, we witnessed a revolution in our understanding of pulmonary hypertension and how this life-threatening disease could be reversed. We are pleased to be combining our efforts with GSK, a leader in respiratory and inflammatory drivers of disease, who shares our vision of HS235’s potential to transform the treatment of this debilitating condition," Ilia Tikhomirov, 35Pharma CEO.